TY - JOUR
T1 - From cancer patients to cancer survivors
T2 - The issue of Cardioncology - A biological perspective
AU - Zambelli, Alberto
AU - Porta, Matteo Della
AU - Rosti, Vittorio
PY - 2010/3
Y1 - 2010/3
N2 - Long-term survival of cancer patients can be worsened by cardiovascular morbidity and mortality due to anticancer treatments based on cardiotoxic or antiangiogenic regimens. Growing scientific evidences support a role for circulating endothelial progenitor cells (EPCs) both in cancer pathogenesis and in cardiovascular diseases. High frequency of circulating EPCs seems to play a role in cancer growth and dissemination by favouring tumor angiogenesis and estabilishment of sites of metastasis. On the other hand, high level of circulating EPCs seems to be associated with a lower risk of developing cardiovascular diseases and with improved vascular regeneration after cardiovascular damage. Here, the possibile opposing roles of circulating EPCs in cancer patients suffering from therapy related-cardiovascular diseases are discussed, under the light of the potential modulation of their levels for therapeutic purposes. This can become a relevant issue in the field of cardioncology, the discipline that deals with the managing and treatment of cancer patients suffering from concomitant cardiovascular diseases or who are exposed to an increased risk to develop therapy related-cardiovascular complications.
AB - Long-term survival of cancer patients can be worsened by cardiovascular morbidity and mortality due to anticancer treatments based on cardiotoxic or antiangiogenic regimens. Growing scientific evidences support a role for circulating endothelial progenitor cells (EPCs) both in cancer pathogenesis and in cardiovascular diseases. High frequency of circulating EPCs seems to play a role in cancer growth and dissemination by favouring tumor angiogenesis and estabilishment of sites of metastasis. On the other hand, high level of circulating EPCs seems to be associated with a lower risk of developing cardiovascular diseases and with improved vascular regeneration after cardiovascular damage. Here, the possibile opposing roles of circulating EPCs in cancer patients suffering from therapy related-cardiovascular diseases are discussed, under the light of the potential modulation of their levels for therapeutic purposes. This can become a relevant issue in the field of cardioncology, the discipline that deals with the managing and treatment of cancer patients suffering from concomitant cardiovascular diseases or who are exposed to an increased risk to develop therapy related-cardiovascular complications.
KW - Cancer survivors
KW - Cardioncology
KW - Cardiotoxicity
KW - Endothelial progenitor cells
UR - http://www.scopus.com/inward/record.url?scp=76049084088&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=76049084088&partnerID=8YFLogxK
U2 - 10.1016/j.ejca.2009.12.011
DO - 10.1016/j.ejca.2009.12.011
M3 - Article
C2 - 20036530
AN - SCOPUS:76049084088
VL - 46
SP - 697
EP - 702
JO - European Journal of Cancer
JF - European Journal of Cancer
SN - 0959-8049
IS - 4
ER -